$1.38
+0.02 (+1.47%)
Open$1.37
Previous Close$1.36
Day High$1.40
Day Low$1.35
52W High$2.23
52W Low$0.85
Volume—
Avg Volume317.7K
Market Cap35.56M
P/E Ratio—
EPS$-0.44
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,169.6% upside
Current
$1.38
$1.38
Target
$31.32
$31.32
$21.60
$31.32 avg
$37.71
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.32M | 9.26M | 9.19M |
| Net Income | 712.1K | 643.5K | 610.9K |
| Profit Margin | 7.6% | 7.0% | 6.7% |
| EBITDA | 971.8K | 983.2K | 961.2K |
| Free Cash Flow | 631.5K | 606.6K | 819.9K |
| Rev Growth | +16.1% | +5.9% | +8.5% |
| Debt/Equity | 1.16 | 1.10 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |